Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
NASDAQ:CDXS
CDXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.43 - $6.08
Previous CloseN/A
Volume271.47K
Average Volume (3M)974.35K
Market Cap
$243.54M
Enterprise Value$172.94M
Total Cash (Recent Filing)$19.26M
Total Debt (Recent Filing)$59.90M
Price to Earnings (P/E)―
Beta3.12
Next Earnings
May 01, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding82,837,310
10 Day Avg. Volume1,027,977
30 Day Avg. Volume974,349
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.56
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$6.67Price Target Upside136.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Codexis News
PremiumCompany Announcements
Codexis Earnings Call: Growth Prospects and Challenges
PremiumCompany Announcements
Codexis Reports 2024 Results, Eyes Growth in 2025
---
Bulls Say, Bears Say
Bulls Say
Cash FlowCodexis has cash to fund operations to cash flow positivity which management expects should occur by YE:26.
FinancingCodexis extended their cash runway into 2027 with a $31M raise, which should increase confidence in the company's ability to reach cash flow positivity.
Long-term OutlookEncouraging progress in Q4 laying the groundwork for ECO's long-term outlook.
Bears Say
PartnershipsExecuting on the right partnerships remains critical to the long-term outlook.
Revenue PerformanceQ4 revenues of $21.5M missed consensus estimates of $27.4M.
---
Ownership Overview
13.42% Insiders
19.21% Mutual Funds
36.61% Other Institutional Investors
20.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CDXS FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was $2.43 and its highest was $6.08 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is $243.54M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is May 01, 2025 which is in 35 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on Feb 27, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.036 by -$0.094.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.23.
How many shares outstanding does Codexis have?
Codexis has 82,837,310 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.036. Following the earnings report the stock price went down -22.646%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CDXS
---
Codexis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (136.52% Upside)
$6.67 (136.52% Upside)
Hedge Fund Trend
Increased
By 212.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.78%
12-Months-Change
Fundamentals
Return on Equity
-85.03%
Trailing 12-Months
Asset Growth
9.12%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
---
CDXS Company Deck
---
CDXS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Codexis demonstrated strong progress in its ECO Synthesis platform and Pharma Biocatalysis business, positioning itself for revenue growth and reduced losses. However, challenges remain in revenue generation without PAXLOVID and improving gross margins.Read More>---
CDXS Stock 12 Month Forecast
Average Price Target
$6.67
▲(136.52% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Denali Therapeutics
―
Best Analysts Covering CDXS
1 Year
1 Year Success Rate
8/24 ratings generated profit
1 Year Average Return
-5.98%
reiterated a buy rating 4 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -5.98% per trade.
---